NCT00959556

Brief Summary

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to chemotherapy. PURPOSE: This clinical trial is studying blood samples in patients with breast cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Nov 2007

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 28, 2007

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

August 13, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 14, 2009

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 6, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 6, 2012

Completed
Last Updated

March 18, 2026

Status Verified

November 1, 2023

Enrollment Period

4.1 years

First QC Date

August 13, 2009

Last Update Submit

March 16, 2026

Conditions

Breast Cancer

Keywords

recurrent breast cancerstage IA breast cancerstage IB breast cancerstage II breast cancerstage IIIA breast cancerstage IIIB breast cancerstage IIIC breast cancerstage IV breast cancer

Outcome Measures

Primary Outcomes (1)

  • Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)

Interventions

laboratory biomarker analysisOTHER

Eligibility Criteria

Age18 Years - 120 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
DISEASE CHARACTERISTICS: * Histologically confirmed breast carcinoma * Received first-line chemotherapy (in neoadjuvant or metastatic setting) comprising anthracyclines and/or taxanes, including for a second primary cancer * Patient agrees to conservative surgery * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * No contraindication for chemotherapy comprising anthracyclines and/or taxanes PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior adjuvant therapy

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Centre Oscar Lambret

Lille, 59020, France

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Jacques Bonneterre, MD, PhD

    Centre Oscar Lambret

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 13, 2009

First Posted

August 14, 2009

Study Start

November 28, 2007

Primary Completion

January 6, 2012

Study Completion

January 6, 2012

Last Updated

March 18, 2026

Record last verified: 2023-11

Locations

FR(1)